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MicroRNAs (miRs) are small non-coding RNAs, which regulate gene expression proﬁles of several genes.
Consequently, miRs control and regulate several vital cellular processes like proliferation, apoptosis,
differentiation, etc. Not surprisingly, altered expression of miRs has been linked to cancer development
and progression. Recent studies have shown that sufﬁciently stable miRs can be isolated from the serum
and other body ﬂuids of cancer patients. The distinct miR proﬁles in the cell free circulating ﬂuids of
cancer patients have a potential to become a new class of biomarkers to detect and prognosticate
cancers. In this review, we ﬁrst brieﬂy address the biogenesis of miRs and their role in gene regulation.
Subsequently, we highlighted the role of miRs in pathogenesis of diseases with an emphasis on cancers.
Finally, since, miRs have been shown to be promising circulating biomarkers for cancer detection, we 1)
summarize the work done to date and 2) highlight the most signiﬁcant advances resulting from these
studies.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
MicroRNAs (miRs) are a family of endogenously synthesized
small non-coding RNAs (approx. 22 nucleotides in length) that
regulate gene expression by 1) inﬂuencing the protein translational
machinery and/or 2) inducing degeneration of target mRNAs.1,2 The
existence and potential function of miRwas ﬁrst described by Lee in
1993 while sequencing lin-4 gene in Caenorhabditis elegans.3 The
explosion of work since then in this area indicates that miRs are
highly conserved among a wide range of species.4 These miR
appear to play important roles in vital cellular processes such as
development, differentiation, cell cycle, apoptosis, metabolism, and
proliferation.5 Thus, it is not surprising that miRs have been
implicated in carcinogenesis. For example, the decreased expres-
sion of miR-Let-7 (highly conservedmiR) has been noted in number
of cancers such as pulmonary, ovarian, gastric and skin.6 Similarly,
miR-221 and miR-222 have been shown to be dysregulated in
glioblastomas, liver and ovarian cancers.7e9 The main aim of this
review is to highlight the role of miRNAs in the pathogenesis,
diagnosis and prognosis of common cancers.
2. MicroRNAs biogenesis and secretion
The biogenesis of the miRs involves three sequential steps: 1)
transcription of primary miR (pri-miRNA) from the miR gene,10 2)nuddin).
pt.
ciates Ltd. Published by Elsevier Ltformation of partially processed precursor miR (pre-miRNA) in the
nuclei11 and 3) maturation of ﬁnal functional miRs in the cyto-
plasm. Synthesized as precursor RNAs (by RNA-polymerase-II),12
they assume hairpin loops and are subsequently cleaved by the
RNAse-III type enzyme Drosha13 and the resulting w70 nt pre-
miRs are transported into the cytoplasm by exportin-5.14 Within
the cytoplasm, the ribonuclease activity of Dicer on pre-miRs
culminates in the production of 21e24 nt RNA duplexes. Single-
strands from these duplexes associate with the argonaute
proteins and direct the argonaute-containing complexes to their
appropriate targets via a WatsoneCrick base-pairing scheme. If
the miRemRNA pairing is perfectly homologous the targeted
mRNA is degraded by the nuclease activity of argonaute. However,
if the miR:mRNA match is only partial, mRNA translation is
inhibited.15 Only a few miRs in animals are perfectly homologous
to their cognate mRNA and are degraded upon annealing. Instead,
a majority of the miRs target multiple mRNAs through a 7 nt
region of homology (the ‘seed’) and inhibit their translation.1 A
schematic diagram illustrates biosynthesis of miRs and their
regulation of gene expression in Fig. 1. Recently, it has been shown
that miRs can be secreted from the cells and may have a role in
intercellular cross talk.16 Several studies have showed that miRs
can be transferred to neighboring cells via exosomes, apoptotic
bodies, shedding vesicles, etc.17e21 Thus, these secreted miRs can
modulate the function of neighboring cells. Moreover, as these
secreted miRs can gain access to body ﬂuids (e.g. blood), they can
be used as relatively non-invasive biomarkers for detecting
disease.d. All rights reserved.
Fig. 1. Describes the steps involved in miRNA Biosynthesis and Processing 1) The miRNAs are transcribed into pri-miRNAs within the nucleus 2) Drosha acts on these pri-miRNAs
and cleaves them into pre-miRNAs (precursor miRNAs) 3) The pre-miRNAs are transported into the cytoplasmwith the help of Exportin 5 4) In the cytoplasm, the hairpin precursors
are cleaved by Dicer, resulting in a small dsRNA duplex that contains both the mature miRNA strand and its complementary strand 5) During the above process, the duplex is
unwound by an unknown helicase-like enzyme and one strand, known as miRNA*, is degraded, whereas the mature miRNA strand, which is 20e25 nucleotides in length 6) These
are then incorporated with RNA induced silencing complex (RISC) 7) The RISC inhibits the function of its target mRNA by mRNA degradation or, most commonly, by translational
repression.
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It is estimated that the human genome contains genes for over
1000 different types of miRs.22 A large number of these miRs
(w600) have already been linked to diverse cellular pathways such
as development, apoptosis, differentiation, proliferation and
metabolism.23 About 50% of miRs are located within the introns of
genes. Based on target prediction analysis it is estimated that the
expression of about 30% of the regulated genes is inﬂuenced by
miRs. MicroRNAs can be classiﬁed according to the degree to which
they inﬂuence the expression of target genes (strongly inhibit,
moderately inhibit, or inconsequential).24 They can also be cate-
gorized on the basis of the degree to which they impact large-scale
biological processes such as morphology, physiology and behavior.
MicroRNAs, which greatly inﬂuence the organismal phenotype, are
referred to as ‘genetic switches’. A third way to categorize miRs is
based on the number of mRNAs they target. If a miR can simulta-
neously repress expression of hundreds of genes and by doing so
control key events during development (i.e., cell-fate determina-
tion, organ formation, etc.) it can be thought of as a global regulator.
Overall, the functions of miRs are to: 1) ﬁne-tune the expression of
their target genes so that it remains within a ‘physiological
window’, 2) serve as a front-line defence system to safeguard a cell
against incoming viruses and 3) prevent accumulation of undesired
products originating from short interspersed elements (SINEs) and
long interspersed elements (LINEs). That a single miR can indeed
inﬂuence the expression of a large number of genes was demon-
strated by expressing the muscle-speciﬁc miR-1 or the brain-
speciﬁc miR-124 in HeLa cells.25 Introduction of either of these
miRs led to the dramatic down regulation of hundreds of genes
containing miR-1 or MiR-124 seed matches shifting the overall
gene expression proﬁles of the transfected HeLa cells toward that of
the tissue from which the respective miR originated.254. MicroRNA and disease
Emerging data demonstrate that differential expression of
miRNA can lead to diseases. This is highlighted by a recent study
which demonstrated that differential expression of miR-1, miR-133,
miR-21 and miR-208 can contribute to various cardiac pathologies,
including ischemic heart disease, arrhythmia and cardiomyop-
athy.26 Studies have shown that miR-155 is important in the
regulation of blood pressure as it suppresses the expression of
angiotensin II type-1 receptor.27 It has also been shown that miR-
192 has an important role in the development of diabetic
nephropathy.28 Further, over-expression of miR 17-92 cluster can
lead to several types of immune complex-mediated renal
diseases.29 Several miRs including miRs-34a, -107, -30d, -124, -296,
-484, -690, and -375 are differentially expressed in hyperglycemia,
a hallmark of diabetes mellitus.30e32 Genetic deletion of miR-375 in
mouse models culminates in animals which are hyperglycemic and
show increased hepatic output of glucose, the latter attributed to
increased alpha cell mass without increased glucagon levels per
cell.33
5. MicroRNAs and cancer
Compelling circumstantial evidence of a widespread miR
deregulation in oncogenesis came from the analysis of the genomic
distribution of 186 miR genes.34 In this study, it was demonstrated
that more than half of them mapped in cancer-associated genomic
regions, namely in chromosomal sites prone to deletions, ampliﬁ-
cations or recombination. Subsequently, a large number of studies
have identiﬁed abnormally expressed miRs in several human
malignancies.35 Similar to their protein-encoding counterparts,
miRs involved in tumorigenesis can be classiﬁed as oncogenes or
tumor suppressors, depending on their expression pattern and
Table 1
MicroRNA targets and functions.
Cancer type miRs Targets/functions Ref
Prostate
cancer
miR-449 Represses HDAC1 (histone
deacetylase 1) and results in growth
retardation in prostate cancer cell
lines.
78e92
miR-145 Targets Fascin homolog 1 (FSCN1),
loss of FSCN1 results in decrease
growth, migration and invasion.
Its overexpression leads to up-
regulation pro-apoptotic genes like
TNFSF10.
miR-205 This miR can post-transcriptionally
limit the amount of DNp63a protein
and thus can control the deposition
of laminin-332 and its receptor.
Thus pathological loss of this miR
prostate cancer can lead into
discontinuity in basement
membrane and tumorigenesis.
It targets N-chimaerin, ERBB3, E2F1,
E2F2, ZEB2, Protein Kinase, Cepsilon
and thus results in decrease growth
and invasion.
This miR induces the expression of
tumor suppressor genes IL24 and
IL32 at both themessenger RNA and
protein levels. This induces growth
arrest and apoptosis in prostate
cancer cells.
miR-21 This miR promotes apoptosis
resistance, motility, and invasion in
prostate cancer cells and by partly
regulating expression of PDCD4,
TPM1, and MARCKS.
It targets tumor suppressor
SMARCA4 (alias BRG1)
Over expression of miR-21 induces
angiogenesis by inducing HIF1 and
VEGF.
miR-15/16 Inhibits cell growth and promotes
cell death by targeting BCL2, MCL1,
CCND1, and WNT3A.
Lung cancer miR-145
miR-143
Targets affected by them are MYC,
ERK5, HOXA9, KRAS, PARP8. miR-
145 down-regulation may be in
sync with EGFR mutations.
66,93e95
Let-7a Let-7a represses NF2 and decreases
chemotherapy-induced apoptosis
in vitro. Target: Caspase-3.
miR-21 Targets: BCL2, MASPIN, PDCD4,
PTEN, TPM1, RECK.
miR-106/93/25
cluster
Reduces apoptotic response after
TGFb stimulation via BIM. Targets:
CDKN1A, E2F1, BIM.
miR 17-92
cluster
Increases tumor growth and
vascularization. Hypothetical
Target includes E2F1. Lowers the
DNA damage in RB-inactivated
small cell lung cancer.
Breast cancer miR-126 Targets: VEGFA and PIK3R2, The
expression of this miR is decreased
in breast cancer.
70,80
miR-355 Loss of miR-335 leads to the
activation of SOX4 and TNC
(encoding tenascin C).
miR-21 Hypothetical Targets: PTEN and
TMP1.
miR-125b Hypothetical Targets: ITG9, YES1,
LIN2810.
Colon cancer miR-34a Down-regulates the E2F signaling
pathway and up-regulating the p53
pathway.
79,65
miR-21 Overexpression in Colon cancer.
Targets include BCL2, MASPIN,
PDCD4, PTEN, TPM1, RECK, RASA1.
Table 1 (continued)
Cancer type miRs Targets/functions Ref
Hepatocellular
carcinoma
miR-224 Hypothetical targets include
PDGFRB (Platelet-derived growth
factor receptor precursor Beta),
RAB9B (Ras-related protein).
67,78
miR-21 Hypothetical Targets include BCL2,
MASPIN, PDCD4, PTEN, TPM1, RECK,
RASA1.
miR-34a Hypothetical Targets: SPTBN2,
E2F3, DLL1, NOTCH 1.
miR-221 Inhibit the expression of the p27KIP
tumor suppressor.
miR-122 Hypothetical targets include GYS1
and CAT-1.
miR-145 Targets: MAP3K3, MAP4K4. YES,
CBFB.
miR-199 Hypothetical targets include JUNB
(jun B proto-oncogene), MED6
(Methyl-CPG binding domain
protein 6), MECP2 (Methyl-CPG-
binding protein 2), CCNL (Cyclin L),
ETS2 (v-ets erythroblastosis virus
E26 oncogene homolog 2).
Ovarian
carcinoma
miR-140 Predicted to target important
molecules as c-SRK, MMP13, and
FGF2.
41
miR-145
miR-125a/b
Hypothetical targets: MAPK
transduction proteins such as
MAP3K3 and MAP4K4 were
predicted targets for miR-145. The
proto-oncogene YES and the core-
binding transcription factor CBFB
were potential targets of both miR-
125 and miR-145. ITGA9 and LIN28
has been predicted to be targets for
miR-125b.
miR-199a/b Hypothetical targets include JUNB
(jun B proto-oncogene), MED6
(Methyl-CPG binding domain
protein 6), MECP2 (Methyl-CPG-
binding protein 2), CCNL (Cyclin L),
ETS2 (v-ets erythroblastosis virus
E26 oncogene homolog 2).
miR-141
miR-200a/b/c
Hypothetical Target: the Tumor
suppressor BAP1, BRCA1-associated
protein. Altered expression of GATA
factors are proposed to be altered
by the miR-200a/b/c mainly.
This table describes the target genes of various miRs in different types of cancers. It
further describes the functional consequence of their expression in different types of
cancers.
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have several factors, including chromosomal rearrangements,37,38
genomic copy number change,34,39,40 epigenetic modiﬁca-
tions,41,42 defects in miR biogenesis pathway,43 and transcriptional
factor induced. In order to investigate the roles of these miRs in
cancer, miR proﬁling of normal vs tumor tissues had been under-
taken. This approach consistently demonstrated deregulation
(primarily down-regulation) of various miRs in tumor tissues.44 For
example, an analysis of 334 samples frommultiple types of cancers
revealed generalized miR expression patterns that were highly
accurate in distinguishing lineage and differentiation state.45 These
results were also indicative of a generalized miR down-regulation
in cancer cells suggesting an essential role of miRs in oncogenic
pathways.43
6. miRs as tumor suppressors and oncomirs
Emerging data have identiﬁed opposing roles of these abnor-
mally expressed miRs in the oncogenic pathways. Let-7 family of
Table 2
Function of microRNAs.
Cancer type Human microRNA Potential
function
Reference
Prostate cancer miR-449, miR-145, miR-146,
miR-330, miR-205
Tumor
suppressor
81e83
miR-21, miR-15/16 Oncogene 81,82
Lung cancer miR-145, miR-143, Let-7a Tumor
suppressor
93,94
miR-21,miR-106/93/25 cluster,
miR 17-92 cluster
Oncogene 66,94,95
Breast cancer miR-126, miR-206 and miR-355 Tumor
suppressor
70
miR-21, miR-125b Oncogene 80
Colon cancer miR-34a Tumor
suppressor
79
miR-21 Oncogene 65
Hepatocellular
carcinoma
miR-224, miR-21, miR-34a,
miR-221, miR-106, miR-303
Tumor
suppressor
78
miR-122, miR-422b, miR-145,
miR-199
Oncogene 67
Ovarian carcinoma miR-140, miR-145, miR-199a/b,
miR-125a/b
Tumor
suppressor
41
miR-141, miR-200a/b/c Oncogene 41
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in lung tumors.46 On a similar note, in leukemic cells, miR-15 and
miR-16 have been shown to target the BCL2 oncogene, leading to its
down-regulation and subsequent apoptosis.47 On the other hand,
certain miRs have exhibited some oncogenic properties. For
example, miR-221 and miR-222 can target and inhibit the expres-
sion of the p27KIP tumor suppressor.48 High levels of these miRs
were shown to maintain low p27 protein leading to elevated
proliferation and cancer. The role of various miRs in cancers is
shown in Tables 1 and 2.Table 3
List of miRNA which can be used for detection of cancer in body ﬂuids.
Cancer type Sample type Circulating microRNA
Prostate cancer Serum miR-141
Urine miR-107, miR-574-3p
Lung cancer Serum miR-25 and miR-223
Serum miR-486, miR-1, miR-30d, miR-499
Sputum miR-21, miR-486, miR-375 and miR-200b
Breast cancer Serum miR-195, Let-7a
Serum miR-21
Serum miR-155
Colon cancer Plasma miR-29a, miR-92a
Plasma miR 17-3p, miR-135b, miR-92, miR-222
Hepatocellular
carcinoma
Serum miR-500
Serum miR-885-5p
Ovarian carcinoma Serum miR-21, miR-92, miR-93, miR-126,
miR-29a, miR-155, miR-
Gastric cancer Plasma miR-106a, miR-21, miR-106b,
Let-7a, miR 17-5p
Whole blood miR-106a, miR-17
Serum MiR-187, miR-371-5p, miR-378
Esophageal cancer Serum miR-10a, miR-22, miR-100, miR-148b,
miR-223, miR-133a, and miR-127-3p)
Serum miR-21, miR-375
Head Neck cancer Plasma miR-184
Serum miR-31
Pancreatic cancer Serum miR-210
Serum miR-200a, miR-200b
Serum MiR-18
Leukemia Serum miR-92a
B-cell lymphoma Serum miR-155, miR-210 and miR-21
Rhabdomyosarcoma Serum miR-206
Malignant melanoma Serum miR-221
A summarized description of studies which were performed using miRs as a biomarkers7. The diagnostic value of microRNAS
An ideal biomarker for detection of cancer should not only be
accessible non-invasively, but should be stable, sensitive, and
speciﬁc. Cell free nucleic acids including DNA, RNA and, more
recently, miRs have shown promise as candidate biomarkers.
Mitchell et al. have shown that miRs present in human plasma are
remarkably stable (i.e., they resist degradation by repeated freeze
thaw cycles and withstand prolonged incubations at room
temperature).49 Strikingly, the miRs are protected from endoge-
nous RNAse activity in human plasma suggesting that they are part
of complexes or in exosomal vesicles. During health, the levels of
cell free miRs in the serum remain stable and any change in the cell
free miR proﬁle is suggestive of a disease state.50,51 For example,
Mitchell et al. provided evidence that plasma miR-141 may be
a potential biomarker for detection of prostate cancer.49 Subse-
quently, Lawrie et al. demonstrated high levels of circulating miR-
21 in the serum of B cell lymphoma patients.52 A recent study by
Huang et al. was able to differentiate colon cancer from normal
controls with 73% sensitivity and 79% speciﬁcity using miR-29 and
miR-92a.53 Chen and colleagues showed that miR-134, miR-146,
miR-221, miR-222 and miR-23a were highly dysregulated in serum
of both lung and colorectal cancer patients.50 In-addition, others
have shown that miRNA can be very speciﬁc for a particular
tumor.54 These studies have paved the way for the surge of activity
in the last few years to identify miRs that could potentially serve as
biomarkers for various cancers. A comprehensive list of miRs used
as biomarkers for detection of cancers is provided in Table 3.
Representative studies highlighting important developments are
addressed below.
MicroRNAs as biomarkers have a potential to offer signiﬁcant
advantages over established biomarkers like CA-125 for ovarian
cancer and Prostate Speciﬁc Antigen (PSA) for prostate cancer. ToTechnology Sample size References
Quantitative RT-PCR 25 patients vs 25 controls 49
Quantitative RT-PCR 78 patients vs 28controls 96
Solexa proﬁling and
Quantitative RT-PCR
152 patients vs 75 healthy controls 50
Quantitative RT-PCR 303 patients vs 1 healthy control 97
Quantitative RT-PCR 36 patients vs 36 healthy control 98
Quantitative RT-PCR 83 patients vs 44 healthy controls 58
Quantitative RT-PCR 102 patients vs 20 healthy controls 57
Quantitative RT-PCR 13 patients vs 8 healthy controls 60
Quantitative RT-PCR 100 patients vs 59 healthy controls 53
Quantitative RT-PCR array 25 patients vs 20 healthy controls 75
Quantitative RT-PCR 10 patients vs no healthy controls 99
Quantitative RT-PCR 46 patients vs 24 healthy controls 100
Quantitative RT-PCR array 9 patients vs 4 healthy controls 55
Quantitative RT-PCR 69 patients vs 30 healthy controls 101
Quantitative RT-PCR 90 patients vs 27 healthy controls 102
Quantitative RT-PCR 40 patients vs 41 controls 103
Solexa proﬁling and QT-PCR 141 patients vs 40 healthy controls 104
Quantitative RT-PCR 50 patients vs 20 healthy controls 105
Quantitative RT-PCR 30 patients vs 38 healthy controls 106
Quantitative RT-PCR 43 patients vs 21 healthy controls 107
Quantitative RT-PCR arrays 22 patients vs 25 healthy controls 108
Quantitative RT-PCR array 45patients vs 32 healthy controls 109
Quantitative RT-PCR array 36 patients vs 30 healthy controls 110
Microarray 2 patients vs 7 healthy controls 76
Quantitative RT-PCR array 60 patients vs 43 healthy controls 52
Quantitative RT-PCR array 10 patients vs 17 healthy controls 111
Quantitative RT-PCR array 94 patients vs 20 healthy controls 112
to detect cancers.
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lated in ovarian cancer patients despite normal CA-125 levels.55
Further, Moltzahn et al. showed that miR expression can be used
to stratify prostate cancer patients according to the risk of
progression.56
In-addition to detecting various cancers, miR levels may prove
useful in determining the stage of various cancers. For example,
Asaga et al. showed that miR-21 expression was elevated in breast
cancer and the level was more pronounced in Stage IV patients.57
As with breast cancer, late stage prostate cancer is associated
with higher expression of miRs. Lodes et al. noted that 15 different
miRs were over-expressed in serum of stage 3 and 4 patients.54
Finally, Heneghan et al. in a large breast cancer study involving
serum samples from 148 patients and 44 healthy controls showed
that miR-195 and let-7a were highly expressed in the patients.
More importantly, the level of these miRs was substantially
reduced upon curative resection.58 The latter study suggests the
intriguing possibility that miRs can be used to track treatment
efﬁcacy.
Speciﬁcity issues related to the ability miRs to serve as
biomarkers have also come to light as a result of recent studies. A
potential for population speciﬁcity has been addressed by Zhao
et al. They showed that in early stage breast cancer patients,
Caucasian American (CA) women had 17 up-regulated and 14
down-regulated miRs compared to 9 up-regulated and 9 down
regulated miRs in African American women.59 Furthermore, cancer
sub-type speciﬁcity can affect the diagnostic power of miRs as
biomarkers. For example, a recent study showed that miR-155 was
elevated in hormone-sensitive, but not in hormone-insensitive
breast cancers.60
8. Prognostic value of microRNAs
The potential clinical utility of miR is not only limited to diag-
nostics, but may also have prognostic value. A series of studies have
shown that miRs are useful indicators of clinical outcome in
a number of cancers.37,61e66 In addition, miRs have been shown to
play a predictive role in determining the tendency for recurrence
and metastasis.65,67e71 MicroRNAs may also be useful indicators of
response to treatment efﬁcacy. In chronic lymphocytic leukemia,
miR-34a can be a marker for chemotherapy resistance and poor
prognosis.72
MicroRNAs also have potential as predictors of progression and
metastasis. miR-122 expression in tumor cells segregates with
speciﬁc gene expression proﬁles linking to hepatocellular carci-
noma (HCC) progression. In-addition, this miR is speciﬁcally
repressed in a subset of primary HCCs that are characterized by
poor prognosis.68 In another large cohort study, prostate-speciﬁc
miR-221 is found to be progressively down-regulated in aggres-
sive forms of prostate cancer. Progressive miR-221 down-regula-
tion is a hallmark of metastasis.73 In esophageal adenocarcinoma,
miR 196awas found to be a potential marker for progression during
Barrett’s metaplasia dysplasia-invasive adenocarcinoma
sequence.74
9. Conclusion
The study of miR proﬁles in different cancers has become an
active area of research. The reason for this enormous interest is
because these stable small RNAs in body ﬂuids of cancer patients
have a potential to become a new class of biomarkers. Several
studies have showed that cell free circulating miRNA can be used as
promising biomarkers to detect cancers. However, association of
grade and stage of different cancers with the speciﬁc expression of
circulating cell free miR is in its infancy and has not as yet yieldedpromising results.75e77 Recent studies indicate a potential for miRs
to be used as markers for cancer outcome and this ﬁeld is slowly
emerging. Therefore, studies on larger cancer populations
addressing the relationships between cell free miR expression and
clinical/pathological parameters are warranted. This work should
be facilitated by recent improvements in methodology (without
enrichment)58 and the application computer-assisted analysis of
data to predict target pathways (algorithms).59
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